CRO MercachemSyncom snaps up Alcami site, boosting chemistry services

petri dishes in a lab
Financial details of MercachemSyncom's recent buy were not disclosed. (science photo/Shutterstock)

Midsized European drug discovery CRO MercachemSyncom has bought Netherlands-based Alcami’s European cGMP CMC drug substance development site, based in Weert.

The CDMO purchase, financials of which were not shared, allows the company to “expand our portfolio of chemistry services from compound design to clinical proof of concept,” Eelco Ebbers, MercachemSyncom CEO, said in a statement.

The deal sees MercachemSyncom now able to better scale up its clinical active pharmaceutical ingredient requirements alongside its site in Prague. “The long experience of the Weert team in designing and driving early clinical drug substance development programs will complement extensive process research capabilities based in Groningen and Nijmegen,” it said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Frank Leemhuis, M.D., managing director at MercachemSyncom, said: “With the addition of the Alcami Weert team, we have the perfect technical and cultural match. With modern, flexible plant capacity, we look forward to supporting many more clinical development programs for our customers.”

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.